•
Dec 31, 2019

SIGA Technologies Q4 2019 Earnings Report

SIGA Technologies reported financial results for fiscal year 2019.

Key Takeaways

SIGA Technologies reported a revenue of approximately $27 million and an operating loss of approximately $2 million for the year ended December 31, 2019. The company's cash and cash equivalents were approximately $161 million at the end of the year. SIGA also announced product delivery expectations for oral TPOXX® and a $50 million share repurchase program.

Revenue for the year ended December 31, 2019, was approximately $27 million.

Operating loss for the year was approximately $2 million.

Net loss per share was $0.15 per diluted share for the year.

Cash and cash equivalents were approximately $161 million at December 31, 2019.

Total Revenue
$4.26M
Previous year: $1.57M
+171.8%
EPS
-$0.06
Previous year: -$4.64
-98.7%
Gross Profit
$210K
Previous year: -$1.51M
-113.9%
Cash and Equivalents
$65.2M
Previous year: $101M
-35.2%
Free Cash Flow
-$14.3M
Previous year: -$3.69M
+287.0%
Total Assets
$199M
Previous year: $203M
-2.4%

SIGA Technologies

SIGA Technologies

SIGA Technologies Revenue by Segment

Forward Guidance

SIGA expects the near-term exercise of procurement options by BARDA under the 19C BARDA Contract worth a total of approximately $101 million for the procurement of 363,070 courses of oral TPOXX® (tecovirimat).

Positive Outlook

  • Near-term exercise of procurement options by BARDA expected.
  • Total of approximately $101 million for the procurement of 363,070 courses of oral TPOXX®.
  • Deliveries of oral TPOXX® to the Strategic National Stockpile (SNS) are expected to start in the second quarter of 2020.
  • Approximately $101 million of oral TPOXX® courses are expected to be delivered to the SNS by April 2021.
  • The 19C BARDA Contract would have up to $414 million of procurement-related options remaining for future exercise.

Challenges Ahead

  • The timing and actual number of shares repurchased will depend on various factors.
  • Exercise of procurement options under government contracts will affect share repurchases.
  • Alternative opportunities for strategic uses of cash will affect share repurchases.
  • The stock price of the Company’s common stock will affect share repurchases.
  • Prior to executing any repurchases under this program, the Company’s current term loan would need to be amended or fully repaid.

Revenue & Expenses

Visualization of income flow from segment revenue to net income